|
1
|
Guldan M, Unlu S, Abdel-Rahman SM, Ozbek
L, Gaipov A, Covic A, Soler MJ, Covic A and Kanbay M: Understanding
the role of sex hormones in cardiovascular kidney metabolic
syndrome: Toward personalized therapeutic approaches. J Clin Med.
13:43542024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ndumele CE, Neeland IJ, Tuttle KR, Chow
SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR,
Després JP, et al: A synopsis of the evidence for the science and
clinical management of cardiovascular-kidney-metabolic (CKM)
syndrome: A scientific statement from the American heart
association. Circulation. 148:1636–1664. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li W, Shen C, Kong W, Zhou X, Fan H, Zhang
Y, Liu Z and Zheng L: Association between the triglyceride
glucose-body mass index and future cardiovascular disease risk in a
population with cardiovascular-kidney-metabolic syndrome stage 0-3:
A nation-wide prospective cohort study. Cardiovasc Diabetol.
23:2922024. View Article : Google Scholar
|
|
4
|
Hoffmann JP, Liu JA, Seddu K and Klein SL:
Sex hormone signaling and regulation of immune function. Immunity.
56:2472–2491. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rajendran A, Minhas AS, Kazzi B, Varma B,
Choi E, Thakkar A and Michos ED: Sex-specific differences in
cardiovascular risk factors and implications for cardiovascular
disease prevention in women. Atherosclerosis. 384:1172692023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levey AS, Titan SM, Powe NR, Coresh J and
Inker LA: Kidney disease, race, and GFR estimation. Clin J Am Soc
Nephrol. 15:1203–1212. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ji H, Sabanayagam C, Matsushita K, Cheng
CY, Rim TH, Sheng B, Li H, Tham YC, Cheng S and Wong TY: Sex
differences in cardiovascular-kidney-metabolic syndrome: 30-year US
trends and mortality risks-brief report. Arterioscler Thromb Vasc
Biol. 45:157–161. 2025. View Article : Google Scholar :
|
|
8
|
Chen JH, Tsai CC, Liu YH, Wu PY, Huang JC,
Chung TL, Su HM and Chen SC: Sex difference in the associations
among hyperuricemia with new-onset chronic kidney disease in a
large taiwanese population follow-up study. Nutrients. 14:38322022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steiger S, Li L, Bruchfeld A, Stevens KI,
Moran SM, Floege J, Caravaca-Fontán F, Mirioglu S, Teng OYK,
Frangou E, et al: Sex dimorphism in kidney health and disease:
Mechanistic insights and clinical implication. Kidney Int.
107:51–67. 2025. View Article : Google Scholar
|
|
10
|
Bucciarelli V, Caterino AL, Bianco F,
Caputi CG, Salerni S, Sciomer S, Maffei S and Gallina S: Depression
and cardiovascular disease: The deep blue sea of women's heart.
Trends Cardiovasc Med. 30:170–176. 2020. View Article : Google Scholar
|
|
11
|
Jovanovic N, Zach V, Crocini C, Bahr LS,
Forslund-Startceva SK and Franz K: A gender perspective on diet,
microbiome, and sex hormone interplay in cardiovascular disease.
Acta Physiol (Oxf). 240:e142282024. View Article : Google Scholar
|
|
12
|
Lau LHY, Nano J, Prehn C, Cecil A,
Rathmann W, Zeller T, Lechner A, Adamski J, Peters A and Thorand B:
Associations of endogenous androgens and sex hormone-binding
globulin with kidney function and chronic kidney disease. Front
Endocrinol (Lausanne). 13:10006502022. View Article : Google Scholar
|
|
13
|
Yin L, Luo M, Wang R, Ye J and Wang X:
Mitochondria in sex hormone-induced disorder of energy metabolism
in males and females. Front Endocrinol (Lausanne). 12:7494512021.
View Article : Google Scholar
|
|
14
|
Rojas R, Clegg DJ and Palmer BF:
Amenorrhea and estrogen disorders in kidney disease. Semin Nephrol.
41:126–132. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gersh F, O'Keefe JH, Elagizi A, Lavie CJ
and Laukkanen JA: Estrogen and cardiovascular disease. Prog
Cardiovasc Dis. 84:60–67. 2024.PubMed/NCBI
|
|
16
|
Zhao D and Guallar E: Testosterone and
cardiovascular disease in men. Ann Intern Med. 175:287–288. 2022.
View Article : Google Scholar
|
|
17
|
Garibotto G, Esposito P, Picciotto D and
Verzola D: Testosterone disorders and male hypogonadism in kidney
disease. Semin Nephrol. 41:114–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu KT, Keen HL, Weatherford ET,
Sequeira-Lopez ML, Gomez RA and Sigmund CD: Estrogen receptor α is
required for maintaining baseline renin expression. Hypertension.
67:992–999. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Connelly PJ, Casey H, Montezano AC, Touyz
RM and Delles C: Sex steroids receptors, hypertension, and vascular
ageing. J Hum Hypertens. 36:120–125. 2022. View Article : Google Scholar :
|
|
20
|
Wiegel RE, Jan Danser AH,
Steegers-Theunissen RPM, Laven JSE, Willemsen SP, Baker VL,
Steegers EAP and von Versen-Höynck F: Determinants of maternal
reninangiotensin-aldosterone-system activation in early pregnancy:
Insights from 2 cohorts. J Clin Endocrinol Metab. 105:3505–3517.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travers S, Martinerie L, Boileau P, Lombès
M and Pussard E: Alterations of adrenal steroidomic profiles in
preterm infants at birth. Arch Dis Child Fetal Neonatal Ed.
103:F143–F151. 2018. View Article : Google Scholar
|
|
22
|
Leśniak K, Rymarz A, Sobol M, Dymus J,
Woźniak-Kosek A and Niemczyk S: Testosterone deficiency and
nutritional parameters as predictors of all-cause mortality among
male dialysis patients. Nutrients. 14:44612022. View Article : Google Scholar
|
|
23
|
Zhou S, Liu Y, Jin L, Guo P, Liu Q, Shan
J, Luo X, He H, Ma W and Zhang T: Estrogen enhances the
cytotoxicity of PARP inhibitors on breast cancer cells through
stimulating nitric oxide production. J Steroid Biochem Mol Biol.
209:1058532021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fredette NC, Meyer MR and Prossnitz ER:
Role of GPER in estrogen-dependent nitric oxide formation and
vasodilation. J Steroid Biochem Mol Biol. 176:65–72. 2018.
View Article : Google Scholar
|
|
25
|
Kim J, Kil IS, Seok YM, Yang ES, Kim DK,
Lim DG, Park JW, Bonventre JV and Park KM: Orchiectomy attenuates
post-ischemic oxidative stress and ischemia/reperfusion injury in
mice. A role for manganese superoxide dismutase. J Biol Chem.
281:20349–20356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tham YK, Bernardo BC, Claridge B, Yildiz
GS, Woon LM, Bond S, Fang H, Ooi JYY, Matsumoto A, Luo J, et al:
Estrogen receptor alpha deficiency in cardiomyocytes reprograms the
heart-derived extracellular vesicle proteome and induces obesity in
female mice. Nat Cardiovasc Res. 2:268–289. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ndzie Noah ML, Adzika GK, Mprah R,
Adekunle AO, Adu-Amankwaah J and Sun H: Sex-gender disparities in
cardiovascular diseases: The effects of estrogen on eNOS, lipid
profile, and NFATs during catecholamine stress. Front Cardiovasc
Med. 8:6399462021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang S, Chen G, Yang Z, Wang D, Lu Y, Zhu
L and Wang X: Testosterone attenuates hypoxia-induced hypertension
by affecting NRF1-mediated transcriptional regulation of ET-1 and
ACE. Hypertens Res. 44:1395–1405. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao C, Gao S, Zhao R, Shen P, Zhu X, Yang
Y, Duan C, Wang Y, Ni H, Zhou L, et al: Association between
systemic immune-inflammation index and
cardiovascular-kidney-metabolic syndrome. Sci Rep. 14:191512024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao Y, Wang W, Xie S, Xu Y and Lin Z:
Joint association of the inflammatory marker and
cardiovascular-kidney-metabolic syndrome stages with all-cause and
cardiovascular disease mortality: A national prospective study. BMC
Public Health. 25:102025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quatrini L, Ricci B, Ciancaglini C, Tumino
N and Moretta L: Regulation of the immune system development by
glucocorticoids and sex hormones. Front Immunol. 12:6728532021.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lakshmikanth T, Consiglio C, Sardh F,
Forlin R, Wang J, Tan Z, Barcenilla H, Rodriguez L, Sugrue J, Noori
P, et al: Immune system adaptation during gender-affirming
testosterone treatment. Nature. 633:155–164. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hodeify R, Megyesi J, Tarcsafalvi A,
Mustafa HI, Hti Lar, Seng NS and Price PM: Gender differences
control the susceptibility to ER stress-induced acute kidney
injury. Am J Physiol Renal Physiol. 304:F875–F882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lou Y, Fu Z, Tian Y, Hu M, Wang Q, Zhou Y,
Wang N, Zhang Q and Jin F: Estrogen-sensitive activation of SGK1
induces M2 macrophages with anti-inflammatory properties and a Th2
response at the maternal-fetal interface. Reprod Biol Endocrinol.
21:502023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shu Z, Zhang G, Zhu X and Xiong W:
Estrogen receptor α mediated M1/M2 macrophages polarization plays a
critical role in NASH of female mice. Biochem Biophys Res Commun.
596:63–70. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hernandez P, O'Brien C, Concors SJ, Wang
Z, Ge G, Hancock WW and Levine MH: The selective estrogen receptor
modulator, raloxifene, is protective against renal
ischemia-reperfusion injury. Transplantation. 106:2166–2171. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Chang Y, Han Z, Ma K, Zeng X and
Li L: Estrogen protects against renal ischemia-reperfusion injury
by regulating Th17/Treg cell immune balance. Dis Markers.
2022:78120992022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang G, Yao Q, Ye Z, Huang Y, Zhang C,
Jiang Y and Xi X: Gender differential expression of AR/miR-21
signaling axis and its protective effect on renal
ischemia-reperfusion injury. Front Cell Dev Biol. 10:8613272022.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kumar P and Brooks HL: Sex-specific
epigenetic programming in renal fibrosis and inflammation. Am J
Physiol Renal Physiol. 325:F578–F594. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ziller N, Kotolloshi R, Esmaeili M,
Liebisch M, Mrowka R, Baniahmad A, Liehr T, Wolf G and Loeffler I:
Sex differences in diabetes- and TGF-β1-induced renal damage.
Cells. 9:22362020. View Article : Google Scholar
|
|
41
|
Ha S, Son M, Kim J, Kim D, Kim MJ, Yoo J,
Kim BM, Kim D, Chung HY and Chung KW: Gender differences in adenine
diet-induced kidney toxicity: The impact of 17β-estradiol on renal
inflammation and fibrosis. Int J Mol Sci. 26:13582025. View Article : Google Scholar
|
|
42
|
Maric C, Sandberg K and Hinojosa-Laborde
C: Glomerulosclerosis and tubulointerstitial fibrosis are
attenuated with 17beta-estradiol in the aging Dahl salt sensitive
rat. J Am Soc Nephrol. 15:1546–1556. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng Q, Bi Y, Feng H, Ding X, Zhang S,
Chen Q, Wang L, Zhang Q, Li Y, Tong H, et al: Activation of
estrogen receptor α inhibits TLR4 signaling in macrophages and
alleviates the instability of atherosclerotic plaques in the
postmenopausal stage. Int Immunopharmacol. 116:1098252023.
View Article : Google Scholar
|
|
44
|
Wang Y, Li G, Chen B, Shakir G, Volz M,
van der Vorst EPC, Maas SL, Geiger M, Jethwa C, Bartelt A, et al:
Myeloid cannabinoid CB1 receptor deletion confers atheroprotection
in male mice by reducing macrophage proliferation in a
sex-dependent manner. Cardiovasc Res. 120:1411–1426. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shields KL, Jarrett CL, Bisconti AV, Park
SH, Craig JC, Broxterman RM and Richardson RS: Preserved
endothelium-independent vascular function with aging in men and
women: Evidence from the peripheral and cerebral vasculature. J
Appl Physiol 1985. 135:559–571. 2023.PubMed/NCBI
|
|
46
|
Musicki B, Lagoda G, Goetz T, La Favor JD
and Burnett AL: Transnitrosylation: A factor in nitric
oxide-mediated penile erection. J Sex Med. 13:808–814. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Moreau KL, Clayton ZS, DuBose LE,
Rosenberry R and Seals DR: Effects of regular exercise on vascular
function with aging: Does sex matter? Am J Physiol Heart Circ
Physiol. 326:H123–H137. 2024. View Article : Google Scholar
|
|
48
|
DuPont JJ, Kenney RM, Patel AR and Jaffe
IZ: Sex differences in mechanisms of arterial stiffness. Br J
Pharmacol. 176:4208–4225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Touyz RM, Rios FJ, Alves-Lopes R, Neves
KB, Camargo LL and Montezano AC: Oxidative stress: A unifying
paradigm in hypertension. Can J Cardiol. 36:659–670.
2020.PubMed/NCBI
|
|
50
|
Potje SR, Martins NS, Benatti MN,
Rodrigues D, Bonato VLD and Tostes RC: The effects of female sexual
hormones on the endothelial glycocalyx. Curr Top Membr. 91:89–137.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Babcock MC, DuBose LE, Witten TL, Stauffer
BL, Hildreth KL, Schwartz RS, Kohrt WM and Moreau KL: Oxidative
stress and inflammation are associated with age-related endothelial
dysfunction in men with low testosterone. J Clin Endocrinol Metab.
107:e500–e514. 2022. View Article : Google Scholar :
|
|
52
|
Vallée A: Menopause and arterial stiffness
index: Insights from the women's UK Biobank cohort. Maturitas.
198:1086082025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guthrie GL, Almutlaq RN, Sugahara S, Butt
MK, Brooks CR, Pollock DM and Gohar EY: G protein-coupled estrogen
receptor 1 regulates renal endothelin-1 signaling system in a
sex-specific manner. Front Physiol. 14:10869732023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nasci VL, Bopassa JC, Mironova E, Rhoads
M, Singh R, Buehler DP, Pollock DM, Pochynyuk OM, Stockand JD and
Gohar EY: Renal G protein-coupled estrogen receptor 1 regulates the
epithelial sodium channel promoting natriuresis to a greater extent
in females. Am J Physiol Renal Physiol. 329:F1–F10. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Harvey BJ and Alvarez de la Rosa D: Sex
differences in kidney health and disease. Nephron. 149:77–103.
2025.
|
|
56
|
Ransick A, Lindström NO, Liu J, Zhu Q, Guo
JJ, Alvarado GF, Kim AD, Black HG, Kim J and McMahon AP:
Single-cell profiling reveals sex, lineage, and regional diversity
in the mouse kidney. Dev Cell. 51:399–413.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bairey Merz CN, Dember LM, Ingelfinger JR,
Vinson A, Neugarten J, Sandberg KL, Sullivan JC, Maric-Bilkan C,
Rankin TL, Kimmel PL, et al: Sex and the kidneys: Current
understanding and research opportunities. Nat Rev Nephrol.
15:776–783. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
McDonough AA, Harris AN, Xiong LI and
Layton AT: Sex differences in renal transporters: Assessment and
functional consequences. Nat Rev Nephrol. 20:21–36. 2024.
View Article : Google Scholar :
|
|
59
|
Meetam P, Srimaroeng C, Soodvilai S and
Chatsudthipong V: Role of estrogen in renal handling of organic
cation, tetraethylammonium: In vivo and in vitro studies. Biol
Pharm Bull. 32:1968–1972. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Doublier S, Lupia E, Catanuto P,
Periera-Simon S, Xia X, Korach K, Berho M, Elliot SJ and Karl M:
Testosterone and 17β-estradiol have opposite effects on podocyte
apoptosis that precedes glomerulosclerosis in female estrogen
receptor knockout mice. Kidney Int. 79:404–413. 2011. View Article : Google Scholar
|
|
61
|
Birch Nielsen C, Krag S, ØSterby R,
Flyvbjerg A, Nyengaard J, Forman A and Wogensen L: Transforming
growth factor beta1-induced glomerulopathy is prevented by
17beta-estradiol supplementation. Virchows Arch. 444:561–566. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gohar EY, Almutlaq RN, Daugherty EM, Butt
MK, Jin C, Pollock JS, Pollock DM and De Miguel C: Activation of G
protein-coupled estrogen receptor 1 ameliorates proximal tubular
injury and proteinuria in Dahl salt-sensitive female rats. Am J
Physiol Regul Integr Comp Physiol. 320:R297–R306. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gohar EY and Pollock DM: Functional
interaction of endothelin receptors in mediating natriuresis evoked
by G protein-coupled estrogen receptor 1. J Pharmacol Exp Ther.
376:98–105. 2021. View Article : Google Scholar :
|
|
64
|
Calhoun DA and Sharma K: The role of
aldosteronism in causing obesity-related cardiovascular risk.
Cardiol Clin. 28:517–527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shukri MZ, Tan JW, Manosroi W, Pojoga LH,
Rivera A, Williams JS, Seely EW, Adler GK, Jaffe IZ, Karas RH, et
al: Biological sex modulates the adrenal and blood pressure
responses to angiotensin II. Hypertension. 71:1083–1090. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gupta DK, Lewis CE, Varady KA, Su YR,
Madhur MS, Lackland DT, Reis JP, Wang TJ, Lloyd-Jones DM and Allen
NB: Effect of dietary sodium on blood pressure: A crossover trial.
JAMA. 330:2258–2266. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Demirci M, Afolabi JM and Kirabo A: Aging
and sex differences in salt sensitivity of blood pressure. Clin Sci
(Lond). 139:199–212. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mehta A, Desai SR, Ko YA, Liu C, Dhindsa
DS, Nayak A, Hooda A, Martini MA, Ejaz K, Sperling LS, et al: Sex
differences in circulating soluble urokinase-type plasminogen
activator receptor (suPAR) levels and adverse outcomes in coronary
artery disease. J Am Heart Assoc. 9:e0154572020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wohlwend NF, Grossmann K, Aeschbacher S,
Weideli OC, Telser J, Risch M, Conen D and Risch L: The association
of suPAR with cardiovascular risk factors in young and healthy
adults. Diagnostics (Basel). 13. pp. 29382023, View Article : Google Scholar
|
|
70
|
Hayek SS, Landsittel DP, Wei C, Zeier M,
Yu ASL, Torres VE, Roth S, Pao CS and Reiser J: Soluble urokinase
plasminogen activator receptor and decline in kidney function in
autosomal dominant polycystic kidney disease. J Am Soc Nephrol.
30:1305–1313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kovács Á, Zhazykbayeva S, Herwig M, Fülöp
GÁ, Csípő T, Oláh N, Hassoun R, Budde H, Osman H, Kaçmaz M, et al:
Sex-specific cardiovascular remodeling leads to a divergent
sex-dependent development of heart failure in aged hypertensive
rats. Geroscience. 46:4543–4561. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Delcuratolo E, Palazzuoli A, Coppi F,
Mattioli AV, Severino P, Tramonte F and Fedele F: Risk factors and
cellular differences in heart failure: The key role of sex
hormones. Biomedicines. 11:30522023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Regitz-Zagrosek V: Sex and gender
differences in heart failure. Int J Heart Fail. 2:157–181. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lam CSP, Arnott C, Beale AL, Chandramouli
C, Hilfiker-Kleiner D, Kaye DM, Ky B, Santema BT, Sliwa K and Voors
AA: Sex differences in heart failure. Eur Heart J. 40:3859–3868c.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
van Ommen AMLN, Canto ED, Cramer MJ,
Rutten FH, Onland-Moret NC and Ruijter HMD: Diastolic dysfunction
and sex-specific progression to HFpEF: Current gaps in knowledge
and future directions. BMC Med. 20:4962022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hsich EM: Sex differences in advanced
heart failure therapies. Circulation. 139:1080–1093. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sullivan K, Doumouras BS, Santema BT,
Walsh MN, Douglas PS, Voors AA and Van Spall HGC: Sex-specific
differences in heart failure: Pathophysiology, risk factors,
management, and outcomes. Can J Cardiol. 37:560–571.
2021.PubMed/NCBI
|
|
78
|
Qiu W, Wang W, Wu S, Zhu Y, Zheng H and
Feng Y: Sex differences in long-term heart failure prognosis: A
comprehensive meta-analysis. Eur J Prev Cardiol. 31:2013–2023.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang N, Evans J, Sawant S, Sindone J and
Lal S: Sex-specific differences in the efficacy of heart failure
therapies: A meta-analysis of 84,818 patients. Heart Fail Rev.
28:949–959. 2023. View Article : Google Scholar
|
|
80
|
Qian C, Liu J and Liu H: Targeting
estrogen receptor signaling for treating heart failure. Heart Fail
Rev. 29:125–131. 2024. View Article : Google Scholar :
|
|
81
|
de Alencar AKN, Wang H, de Oliveira GMM,
Sun X, Zapata-Sudo G and Groban L: Crossroads between estrogen
loss, obesity, and heart failure with preserved ejection Fraction.
Arq Bras Cardiol. 117:1191–1201. 2021.In English, Portuguese.
|
|
82
|
Njoroge JN, Tressel W, Biggs ML, Matsumoto
AM, Smith NL, Rosenberg E, Hirsch CH, Gottdiener JS, Mukamal KJ and
Kizer JR: Circulating androgen concentrations and risk of incident
heart failure in older men: The cardiovascular health study. J Am
Heart Assoc. 11:e0269532022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lim J, Hashemian M, Blechter B, Roger VL
and Wong JYY: Pre-diagnostic free androgen and estradiol levels
influence heart failure risk in both women and men: A prospective
cohort study in the UK Biobank. Eur J Heart Fail. 26:540–550. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Honigberg MC and Givertz MM: Peripartum
cardiomyopathy. BMJ. 364:k52872019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Akinrinade O, Lesurf R; Genomics England
Research Consortium; Lougheed J, Mondal T, Smythe J,
Altamirano-Diaz L, Oechslin E and Mital S: Age and sex differences
in the genetics of cardiomyopathy. J Cardiovasc Transl Res.
16:1287–1302. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Matilla L, Martín-Núñez E, Garaikoetxea M,
Navarro A, Tamayo I, Fernández-Celis A, Gainza A,
Fernández-Irigoyen J, Santamaría E, Muntendam P, et al:
Sex-specific role of galectin-3 in aortic stenosis. Biol Sex
Differ. 14:722023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Suthahar N, Lau ES, Blaha MJ, Paniagua SM,
Larson MG, Psaty BM, Benjamin EJ, Allison MA, Bartz TM, Januzzi JL
Jr, et al: Sex-specific associations of cardiovascular risk factors
and biomarkers with incident heart failure. J Am Coll Cardiol.
76:1455–1465. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ko SH and Jung Y: Energy metabolism
changes and dysregulated lipid metabolism in postmenopausal women.
Nutrients. 13:45562021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Holven KB and Roeters van Lennep J: Sex
differences in lipids: A life course approach. Atherosclerosis.
384:1172702023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Mauvais-Jarvis F: Sex differences in
energy metabolism: Natural selection, mechanisms and consequences.
Nat Rev Nephrol. 20:56–69. 2024. View Article : Google Scholar
|
|
91
|
Tabassum R, Ruotsalainen S, Ottensmann L,
Gerl MJ, Klose C, Tukiainen T, Pirinen M, Simons K, Widén E and
Ripatti S: Lipidome- and genome-wide study to understand sex
differences in circulatory lipids. J Am Heart Assoc.
11:e0271032022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tramunt B, Smati S, Grandgeorge N, Lenfant
F, Arnal JF, Montagner A and Gourdy P: Sex differences in metabolic
regulation and diabetes susceptibility. Diabetologia. 63:453–461.
2020. View Article : Google Scholar :
|
|
93
|
Kautzky-Willer A, Harreiter J and Pacini
G: Sex and gender differences in risk, pathophysiology and
complications of type 2 diabetes mellitus. Endocr Rev. 37:278–316.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
MacGregor K, Ellefsen S, Pillon NJ,
Hammarström D and Krook A: Sex differences in skeletal muscle
metabolism in exercise and type 2 diabetes mellitus. Nat Rev
Endocrinol. 21:166–179. 2025. View Article : Google Scholar
|
|
95
|
Whipple MO, Pinto AJ, Abushamat LA,
Bergouignan A, Chapman K, Huebschmann AG, Masters KS, Nadeau KJ,
Scalzo RL, Schauer IE, et al: Sex differences in physical activity
among individuals with type 2 diabetes across the life span: A
systematic review and meta-analysis. Diabetes Care. 45:2163–2177.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kesavadev J, Abraham G, Chandni R, Chawla
P, Nambiar A, Deshpande N, Joshi S, Jothydev S, Krishnan G and Das
AK: Type 2 diabetes in women: Differences and difficulties. Curr
Diabetes Rev. 18:e0812211986512022. View Article : Google Scholar
|
|
97
|
Ohkuma T, Iwase M, Fujii H and Kitazono T:
Sex differences in cardiovascular risk, lifestyle, and
psychological factors in patients with type 2 diabetes: The Fukuoka
diabetes registry. Biol Sex Differ. 14:322023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ju SH and Yi HS: Implication of sex
differences in visceral fat for the assessment of incidence risk of
type 2 diabetes mellitus. Diabetes Metab J. 46:414–416. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Pan R and Chen Y: Fat biology and
metabolic balance: On the significance of sex. Mol Cell Endocrinol.
533:1113362021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ramirez MF, Pan AS, Parekh JK, Owunna N,
Courchesne P, Larson MG, Levy D, Murabito JM, Ho JE and Lau ES: Sex
differences in protein biomarkers and measures of fat distribution.
J Am Heart Assoc. 13:e0002232024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Bancks MP, Akhabue E, Rana JS, Reis JP,
Schreiner PJ, Yano Y and Lewis CE: Sex differences in
cardiovascular risk factors before and after the development of
type 2 diabetes and risk for incident cardiovascular disease.
Diabetes Res Clin Pract. 166:1083342020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Johnson ML, Preston JD, Rashid CS, Pearson
KJ and Ham JN: Sex differences in type 2 diabetes: An opportunity
for personalized medicine. Biol Sex Differ. 14:882023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
de Ritter R, de Jong M, Vos RC, van der
Kallen CJH, Sep SJS, Woodward M, Stehouwer CDA, Bots ML and Peters
SAE: Sex differences in the risk of vascular disease associated
with diabetes. Biol Sex Differ. 11:12020. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Maric-Bilkan C: Sex differences in micro-
and macro-vascular complications of diabetes mellitus. Clin Sci
(Lond). 131:833–846. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Jia F, Fei SF, Tong DB, Xue C and Li JJ:
Sex difference in circulating PCSK9 and its clinical implications.
Front Pharmacol. 13:9538452022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Rivera FB, Cha SW, Aparece JP, Rocimo A,
Ong BA, Golbin JM, Alfonso PG, Enkhmaa B, Khan SU, Cainzos-Achirica
M, et al: Sex differences in cardiovascular outcomes and
cholesterol-lowering efficacy of PCSK9 inhibitors: Systematic
review and meta-analysis. JACC Adv. 2:1006692023. View Article : Google Scholar
|
|
107
|
Ji H, Kwan AC, Chen MT, Ouyang D, Ebinger
JE, Bell SP, Niiranen TJ, Bello NA and Cheng S: Sex differences in
myocardial and vascular aging. Circ Res. 130:566–577. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Theofilatos K, Stojkovic S, Hasman M, van
der Laan SW, Baig F, Barallobre-Barreiro J, Schmidt LE, Yin S, Yin
X, Burnap S, et al: Proteomic atlas of atherosclerosis: The
contribution of proteoglycans to sex differences, plaque
phenotypes, and outcomes. Circ Res. 133:542–558. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Shuaishuai D, Jingyi L, Zhiqiang Z and
Guanwei F: Sex differences and related estrogenic effects in heart
failure with preserved ejection fraction. Heart Fail Rev.
28:937–948. 2023. View Article : Google Scholar
|
|
110
|
Chyou JY, Qin H, Butler J, Voors AA and
Lam CSP: Sex-related similarities and differences in responses to
heart failure therapies. Nat Rev Cardiol. 21:498–516. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
García GG, Iyengar A, Kaze F, Kierans C,
Padilla-Altamira C and Luyckx VA: Sex and gender differences in
chronic kidney disease and access to care around the globe. Semin
Nephrol. 42:101–113. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chesnaye NC, Carrero JJ, Hecking M and
Jager KJ: Differences in the epidemiology, management and outcomes
of kidney disease in men and women. Nat Rev Nephrol. 20:7–20. 2024.
View Article : Google Scholar
|
|
113
|
Carrero JJ, Hecking M, Chesnaye NC and
Jager KJ: Sex and gender disparities in the epidemiology and
outcomes of chronic kidney disease. Nat Rev Nephrol. 14:151–164.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Kozaki Y, Morinaga T, Fukatsu A, Ito T,
Ishimoto T, Kosugi T, Inaguma D, Tamai H and Maruyama S: Sex
differences in clinical outcomes in Japanese incident dialysis
patients: A prospective observational multicenter study. Clin Exp
Nephrol. 26:466–475. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Raffray M, Bourasseau L, Vigneau C,
Couchoud C, Béchade C, Glowacki F and Bayat S: Sex-related
differences in pre-dialysis trajectories and dialysis initiation: A
French nationwide retrospective study. PLoS One. 19:e02996012024.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Cobo G, Hecking M, Port FK, Exner I,
Lindholm B, Stenvinkel P and Carrero JJ: Sex and gender differences
in chronic kidney disease: Progression to end-stage renal disease
and haemodialysis. Clin Sci (Lond). 130:1147–1163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Shepard BD: Sex differences in diabetes
and kidney disease: Mechanisms and consequences. Am J Physiol Renal
Physiol. 317:F456–F462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhao B, Hong Z, Wei Y, Yu D, Xu J and
Zhang W: Erectile dysfunction predicts cardiovascular events as an
independent risk factor: A systematic review and meta-analysis. J
Sex Med. 16:1005–1017. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Cipriani S and Simon JA: Sexual
dysfunction as a harbinger of cardiovascular disease in
postmenopausal women: How far are we? J Sex Med. 19:1321–1332.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Sansone A, Mollaioli D, Ciocca G, Limoncin
E, Colonnello E and Jannini EA: Sexual dysfunction in men and women
with diabetes: A reflection of their complications? Curr Diabetes
Rev. 18:e0308211921472022. View Article : Google Scholar
|
|
121
|
Imprialos KP, Stavropoulos K, Doumas M,
Tziomalos K, Karagiannis A and Athyros VG: Sexual dysfunction,
cardiovascular risk and effects of pharmacotherapy. Curr Vasc
Pharmacol. 16:130–142. 2018. View Article : Google Scholar
|
|
122
|
Kouhpeikar H, Delbari Z, Sathyapalan T,
Simental-Mendía LE, Jamialahmadi T and Sahebkar A: The effect of
statins through mast cells in the pathophysiology of
atherosclerosis: A review. Curr Atheroscler Rep. 22:192020.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
van Oortmerssen JAE, Mulder JWCM, van der
Bijl MF, Mijnster RJM, Kavousi M and Roeters van Lennep JE; IMPRESS
consortium: Lipid lowering therapy utilization and lipid goal
attainment in women. Curr Atheroscler Rep. 27:292025. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Gavina C, Araújo F, Teixeira C, Ruivo JA,
Corte-Real AL, Luz-Duarte L, Canelas-Pais M and Taveira-Gomes T:
Sex differences in LDL-C control in a primary care population: The
PORTRAIT-DYS study. Atherosclerosis. 384:1171482023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Mulder J, Tromp TR, Al-Khnifsawi M, Mulder
JWCM, Tromp TR, Al-Khnifsawi M, Blom DJ, Chlebus K, Cuchel M,
D'Erasmo L, et al: Sex differences in diagnosis, treatment, and
cardiovascular outcomes in homozygous familial
hypercholesterolemia. JAMA Cardiol. 9:313–322. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Cholesterol Treatment Trialists' (CTT)
Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes
J, Barnes EH, Voysey M, Gray A, Collins R and Baigent C: The
effects of lowering LDL cholesterol with statin therapy in people
at low risk of vascular disease: Meta-analysis of individual data
from 27 randomised trials. Lancet. 380:581–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ames MK, Atkins CE and Pitt B: The
renin-angiotensin-aldosterone system and its suppression. J Vet
Intern Med. 33:363–382. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Te Riet L, van Esch JH, Roks AJ, van den
Meiracker AH and Danser AH: Hypertension:
Renin-angiotensin-aldosterone system alterations. Circ Res.
116:960–975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Song JJ, Ma Z, Wang J, Chen LX and Zhong
JC: Gender differences in hypertension. J Cardiovasc Transl Res.
13:47–54. 2020. View Article : Google Scholar
|
|
130
|
Kostis WJ, Shetty M, Chowdhury YS and
Kostis JB: ACE inhibitor-induced angioedema: A review. Curr
Hypertens Rep. 20:552018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Hudson M, Rahme E, Behlouli H, Sheppard R
and Pilote L: Sex differences in the effectiveness of angiotensin
receptor blockers and angiotensin converting enzyme inhibitors in
patients with congestive heart failure-a population study. Eur J
Heart Fail. 9:602–609. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sullivan JC, Rodriguez-Miguelez P,
Zimmerman MA and Harris RA: Differences in angiotensin (1-7)
between men and women. Am J Physiol Heart Circ Physiol.
308:H1171–H1176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Kjaergaard KD, Peters CD, Jespersen B,
Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby
BM, Strandhave C and Jensen JD: Angiotensin blockade and
progressive loss of kidney function in hemodialysis patients: A
randomized controlled trial. Am J Kidney Dis. 64:892–901. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Parksook WW, Heydarpour M, Gholami SK,
Luther JM, Hopkins PN, Pojoga LH and Williams JS: Salt sensitivity
of blood pressure and aldosterone: Interaction between the
lysine-specific demethylase 1 gene, sex, and age. J Clin Endocrinol
Metab. 107:1294–1302. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Faulkner JL and Belin de Chantemèle EJ:
Female sex, a major risk factor for salt-sensitive hypertension.
Curr Hypertens Rep. 22:992020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Cheng J, Zhang W, Zhang X, Han F, Li X, He
X, Li Q and Chen J: Effect of angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers on all-cause
mortality, cardiovascular deaths, and cardiovascular events in
patients with diabetes mellitus: A meta-analysis. JAMA Intern Med.
174:773–785. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Shin J, Kim H, Yim HW, Kim JH, Lee S and
Kim HS: Angiotensin-converting enzyme inhibitors versus angiotensin
receptor blockers: New-onset diabetes mellitus stratified by statin
use. J Clin Pharm Ther. 47:97–103. 2022. View Article : Google Scholar
|
|
138
|
Morrow DA, Velazquez EJ, Desai AS, DeVore
AD, Lepage S, Park JG, Sharma K, Solomon SD, Starling RC, Ward JH,
et al: Sacubitril/valsartan in patients hospitalized with
decompensated heart failure. J Am Coll Cardiol. 83:1123–1132. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Vallon V and Verma S: Effects of SGLT2
inhibitors on kidney and cardiovascular function. Annu Rev Physiol.
83:503–528. 2021. View Article : Google Scholar
|
|
140
|
Heerspink HJL, Karasik A, Thuresson M,
Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez
LA, Cea-Soriano L, Kohsaka S, et al: Kidney outcomes associated
with use of SGLT2 inhibitors in real-world clinical practice
(CVD-REAL 3): A multinational observational cohort study. Lancet
Diabetes Endocrinol. 8:27–35. 2020. View Article : Google Scholar
|
|
141
|
Simms-Williams N, Treves N, Yin H, Lu S,
Yu O, Pradhan R, Renoux C, Suissa S and Azoulay L: Effect of
combination treatment with glucagon-like peptide-1 receptor
agonists and sodium-glucose cotransporter-2 inhibitors on incidence
of cardiovascular and serious renal events: Population based cohort
study. BMJ. 385:e0782422024. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Singh AK and Singh R: Gender difference in
cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor
agonist in type 2 diabetes: A systematic review and meta-analysis
of cardio-vascular outcome trials. Diabetes Metab Syndr.
14:181–187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Htoo PT, Tesfaye H, Schneeweiss S, Wexler
DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A,
Paik JM and Patorno E: Cardiorenal effectiveness of empagliflozin
vs glucagon-like peptide-1 receptor agonists: Final-year results
from the EMPRISE study. Cardiovasc Diabetol. 23:572024. View Article : Google Scholar
|
|
144
|
Ali MU, Mancini GBJ, Fitzpatrick-Lewis D,
Lewis R, Jovkovic M, Zieroth S, O'Meara E, Connelly KA and
Sherifali D: The effectiveness of sodium-glucose cotransporter 2
inhibitors and glucagon-like peptide-1 receptor agonists on
cardiorenal outcomes: Systematic review and meta-analysis. Can J
Cardiol. 38:1201–1210. 2022.PubMed/NCBI
|
|
145
|
Wang X, Vaduganathan M, Claggett BL, Hegde
SM, Pabon M, Kulac IJ, Vardeny O, O'Meara E, Zieroth S, Katova T,
et al: Sex differences in characteristics, outcomes, and treatment
response with dapagliflozin across the range of ejection fraction
in patients with heart failure: Insights from DAPA-HF and DELIVER.
Circulation. 147:624–634. 2023. View Article : Google Scholar
|
|
146
|
Yu MK, Vart P, Jongs N, Correa-Rotter R,
Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde
AM, et al: Effects of dapagliflozin in chronic kidney disease
across the spectrum of age and by sex. J Gen Intern Med.
39:921–930. 2024. View Article : Google Scholar :
|
|
147
|
Dave CV, Schneeweiss S, Kim D, Fralick M,
Tong A and Patorno E: Sodium-glucose cotransporter-2 inhibitors and
the risk for severe urinary tract infections: A population-based
cohort study. Ann Intern Med. 171:248–256. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Confederat LG, Condurache MI, Alexa RE and
Dragostin OM: Particularities of urinary tract infections in
diabetic patients: A concise review. Medicina (Kaunas).
59:17472023. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Cox ZL, Collins SP, Aaron M, Hernandez GA,
Iii ATM, Davidson BT, Fowler M, Lindsell CJ Jr; FEH; Jenkins CA, et
al: Efficacy and safety of dapagliflozin in acute heart failure:
Rationale and design of the DICTATE-AHF trial. Am Heart J.
232:116–124. 2021. View Article : Google Scholar
|
|
150
|
Pruett JE, Lirette ST, Romero DG and Yanes
Cardozo LL: Sodium-glucose cotransporter-2 inhibition benefits in
cardiorenal risk in men and women. J Endocr Soc. 7:bvac1912022.
View Article : Google Scholar
|
|
151
|
Alicic RZ, Neumiller JJ and Tuttle KR:
Combination therapy: An upcoming paradigm to improve kidney and
cardiovascular outcomes in chronic kidney disease. Nephrol Dial
Transplant. 40(Suppl 1): i3–i17. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Badve SV, Bilal A, Lee MMY, Sattar N,
Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey
KW, et al: Effects of GLP-1 receptor agonists on kidney and
cardiovascular disease outcomes: A meta-analysis of randomised
controlled trials. Lancet Diabetes Endocrinol. 13:15–28. 2025.
View Article : Google Scholar
|
|
153
|
Yang CT, Yang CY, Ou HT and Kuo S:
Comparative cardiovascular safety of GLP-1 receptor agonists versus
other glucose-lowering agents in real-world patients with type 2
diabetes: A nationwide population-based cohort study. Cardiovasc
Diabetol. 19:832020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Riccio A, Fortin E, Mellbin L, Norhammar
A, Näsman P, Rydén L, Sesti G and Ferrannini G: Sex differences in
the association between insulin resistance and non-fatal myocardial
infarction across glycaemic states. Cardiovasc Diabetol. 23:252024.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Brownrigg GP, Xia YH, Chu CMJ, Wang S,
Chao C, Zhang JA, Skovsø S, Panzhinskiy E, Hu X, Johnson JD and
Rideout EJ: Sex differences in islet stress responses support
female β cell resilience. Mol Metab. 69:1016782023. View Article : Google Scholar
|
|
156
|
de Jong M, Oskam MJ, Sep SJS, Ozcan B,
Rutters F, Sijbrands EJG, Elders PJM, Siegelaar SE, DeVries JH,
Tack CJ, et al: Sex differences in cardiometabolic risk factors,
pharmacological treatment and risk factor control in type 2
diabetes: Findings from the Dutch diabetes pearl cohort. BMJ Open
Diabetes Res Care. 8:e0013652020. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Gado M, Tsaousidou E, Bornstein SR and
Perakakis N: Sex-based differences in insulin resistance. J
Endocrinol. 261:e2302452024. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Palmer SC, Tendal B, Mustafa RA, Vandvik
PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V,
et al: Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors
and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2
diabetes: Systematic review and network meta-analysis of randomised
controlled trials. BMJ. 372:m45732021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Neuen BL, Heerspink HJL, Vart P, Claggett
BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson
SA, Mahaffey KW, et al: Estimated lifetime cardiovascular, kidney,
and mortality benefits of combination treatment with SGLT2
inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared
with conventional care in patients with type 2 diabetes and
albuminuria. Circulation. 149:450–462. 2024. View Article : Google Scholar
|
|
160
|
Rademaker D, de Wit L, Duijnhoven RG,
Voormolen DN, Mol BW, Franx A, DeVries JH, Painter RC, an Rijn BB;
SUGAR-DIP Study Group; et al: Oral glucose-lowering agents vs
insulin for gestational diabetes: A randomized clinical trial.
JAMA. 333:470–478. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Apridonidze T, Essah PA, Iuorno MJ and
Nestler JE: Prevalence and characteristics of the metabolic
syndrome in women with polycystic ovary syndrome. J Clin Endocrinol
Metab. 90:1929–1935. 2005. View Article : Google Scholar
|
|
162
|
Tay CT, Mousa A, Vyas A, Pattuwage L,
Tehrani FR and Teede H: 2023 International evidence-based
polycystic ovary syndrome guideline update: Insights from a
systematic review and meta-analysis on elevated clinical
cardiovascular disease in polycystic ovary syndrome. J Am Heart
Assoc. 13:e0335722024. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Peng H, Ren J, Zhao Y, Fang X, Wang X, Liu
C and Wan Z: Unraveling the connection between PCOS and renal
complications: Current insights and future directions. Diabetes Res
Clin Pract. 224:1122352025. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Yoshida Y, Chen Z, Baudier RL,
Krousel-Wood M, Anderson AH, Fonseca VA and Mauvais-Jarvis F: Sex
differences in the progression of metabolic risk factors in
diabetes development. JAMA Netw Open. 5. pp. e22220702022,
View Article : Google Scholar
|
|
165
|
Franconi F and Campesi I:
Pharmacogenomics, pharmacokinetics and pharmacodynamics:
Interaction with biological differences between men and women. Br J
Pharmacol. 171:580–594. 2014. View Article : Google Scholar
|
|
166
|
Zanger UM and Schwab M: Cytochrome P450
enzymes in drug metabolism: Regulation of gene expression, enzyme
activities, and impact of genetic variation. Pharmacol Ther.
138:103–141. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Yoon S, Jeong S, Jung E, Kim KS, Jeon I,
Lee Y, Cho JY, Oh WY and Chung JY: Effect of CYP3A4 metabolism on
sex differences in the pharmacokinetics and pharmacodynamics of
zolpidem. Sci Rep. 11:191502021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Naidoo P and Chetty M: Progress in the
consideration of possible sex differences in drug interaction
studies. Curr Drug Metab. 20:114–123. 2019. View Article : Google Scholar
|
|
169
|
Klein SL and Flanagan KL: Sex differences
in immune responses. Nat Rev Immunol. 16:626–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Yılmaz İ: Angiotensin-converting enzyme
inhibitors induce cough. Turk Thorac J. 20:36–42. 2019. View Article : Google Scholar
|
|
171
|
Dubey P, Reddy S, Sharma K, Johnson S,
Hardy G and Dwivedi AK: Polycystic ovary syndrome, insulin
resistance, and cardiovascular disease. Curr Cardiol Rep.
26:483–495. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Hirvensalo P, Tornio A, Launiainen T,
Paile-Hyvärinen M, Tapaninen T, Neuvonen M, Backman JT and Niemi M:
UGT1A3 and sex are major determinants of telmisartan
pharmacokinetics-A comprehensive pharmacogenomic study. Clin
Pharmacol Ther. 108:885–895. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Yasar U, Forslund-Bergengren C, Tybring G,
Dorado P, Llerena A, Sjöqvist F, Eliasson E and Dahl ML:
Pharmacokinetics of losartan and its metabolite E-3174 in relation
to the CYP2C9 genotype. Clin Pharmacol Ther. 71:89–98. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ruggenenti P, Perna A, Zoccali C, Gherardi
G, Benini R, Testa A and Remuzzi G: Chronic proteinuric
nephropathies. II. Outcomes and response to treatment in a
prospective cohort of 352 patients: Differences between women and
men in relation to the ACE gene polymorphism. Gruppo Italiano di
Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol.
11:88–96. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Melin J, Tang W, Rekić D, Hamrén B,
Penland RC, Boulton DW and Parkinson J: Dapagliflozin
pharmacokinetics is similar in adults with type 1 and type 2
diabetes mellitus. J Clin Pharmacol. 62:1227–1235. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Li D, Wang T, Shen S, Fang Z, Dong Y and
Tang H: Urinary tract and genital infections in patients with type
2 diabetes treated with sodium-glucose co-transporter 2 inhibitors:
A meta-analysis of randomized controlled trials. Diabetes Obes
Metab. 19:348–355. 2017. View Article : Google Scholar
|
|
177
|
Taylor SI, Cherng HR, Shahidzadeh Yazdi Z,
Montasser ME, Whitlatch HB, Mitchell BD, Shuldiner AR, Streeten EA
and Beitelshees AL: Pharmacogenetics of sodium-glucose
co-transporter-2 inhibitors: Validation of a sex-agnostic
pharmacodynamic biomarker. Diabetes Obes Metab. 25:3512–3520. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
O'Donoghue ML, Kato ET, Mosenzon O, Murphy
SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P,
Gause-Nilsson I, et al: The efficacy and safety of dapagliflozin in
women and men with type 2 diabetes mellitus. Diabetologia.
64:1226–1234. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Overgaard RV, Petri KC, Jacobsen LV and
Jensen CB: Liraglutide 3.0 mg for weight management: A population
pharmacokinetic analysis. Clin Pharmacokinet. 55:1413–1422. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Carlsson Petri KC, Hale PM, Hesse D,
Rathor N and Mastrandrea LD: Liraglutide pharmacokinetics and
exposureresponse in adolescents with obesity. Pediatr Obes.
16:e127992021. View Article : Google Scholar
|
|
181
|
Wilding JPH, Overgaard RV, Jacobsen LV,
Jensen CB and le Roux CW: Exposure-response analyses of liraglutide
3.0 mg for weight management. Diabetes Obes Metab. 18:491–499.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Raparelli V, Elharram M, Moura CS,
Abrahamowicz M, Bernatsky S, Behlouli H and Pilote L: Sex
differences in cardiovascular effectiveness of newer
glucose-lowering drugs added to metformin in type 2 diabetes
mellitus. J Am Heart Assoc. 9:e0129402020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Yang Y, He L, Han S, Yang N, Liu Y, Wang
X, Li Z, Ping F, Xu L, Li W, et al: Sex differences in the efficacy
of glucagon-like peptide-1 receptor agonists for weight reduction:
A systematic review and meta-analysis. J Diabetes. 17:e700632025.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Milani I, Guarisco G, Chinucci M, Gaita C,
Leonetti F and Capoccia D: Sex-differences in response to treatment
with liraglutide 3.0 mg. J Clin Med. 13:33692024. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
de Vries ST, Denig P, Ekhart C, Mol PGM
and van Puijenbroek EP: Sex Differences in adverse drug reactions
of metformin: A longitudinal survey study. Drug Saf. 43:489–495.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Bonnet F and Scheen A: Understanding and
overcoming metformin gastrointestinal intolerance. Diabetes Obes
Metab. 19:473–481. 2017. View Article : Google Scholar
|
|
187
|
Yeung EH, Zhang C, Mumford SL, Ye A,
Trevisan M, Chen L, Browne RW, Wactawski-Wende J and Schisterman
EF: Longitudinal study of insulin resistance and sex hormones over
the menstrual cycle: The BioCycle study. J Clin Endocrinol Metab.
95:5435–5442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
MacGregor KA, Gallagher IJ and Moran CN:
Relationship between insulin sensitivity and menstrual cycle is
modified by BMI, fitness, and physical activity in NHANES. J Clin
Endocrinol Metab. 106:2979–2990. 2021. View Article : Google Scholar : PubMed/NCBI
|
